Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $35.09 C

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has received a consensus rating of “Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have issued a report on the stock in […]

Related Keywords

United States , America , Briggs Morrison , Syndax Pharmaceuticals Trading , Blackrock Inc , Analyst Recommendations For Syndax Pharmaceuticals , Barclays , Vanguard Group Inc , Scotiabank , Syndax Pharmaceuticals Company Profile , Jennison Associates , Insider Activity At Syndax Pharmaceuticals , Nasdaq , Goldman Sachs Group , Syndax Pharmaceuticals , News Ratings For Syndax Pharmaceuticals Daily , Syndax Pharmaceuticals Inc , Get Free Report , Director Briggs Morrison , Street Corp , Capital Management , Get Free , Syndax Pharmaceuticals Daily , Nasdaq Sndx , Sndx , Medical , Ratings , Consensus ,